Ranexa 750mg Ranolazine 60 tablets
Description
BRAND NAME: Ranexa
ABOUT THE PRODUCT:
Ranexa (Ranolazine) is a specialized, long-acting medication designed to help manage the symptoms of chronic stable angina, a condition characterized by chest pain or pressure. By optimizing how your heart muscle uses oxygen, Ranexa helps you maintain your daily activities with greater comfort and fewer interruptions. It serves as an essential add-on therapy for individuals who need additional support when first-line heart medications are not fully effective or tolerated, helping you lead a more active and symptom-free life.
BENEFITS & KEY FEATURES:
- Enhanced Heart Efficiency: Helps the heart muscle function more efficiently by improving oxygen utilization, which reduces the frequency of chest pain episodes.
- Flexible Integration: Specifically formulated to work alongside other common heart treatments, such as beta-blockers or calcium channel blockers, to provide comprehensive symptom control.
- Consistent Support: The prolonged-release formula ensures a steady release of the active ingredient, helping to maintain stable levels throughout the day and night.
HOW TO USE SAFELY:
- Directions: Ranexa should be taken twice daily, with or without food. The tablets must be swallowed whole with water. Do not crush, break, or chew the tablets, as this interferes with the specialized release mechanism.
- Important Tips: Consistency is key to symptom management; try to take your dose at the same time each morning and evening. Avoid consuming grapefruit or grapefruit juice, as these can interfere with how your body processes the medication. Keep your tablets in their original packaging at room temperature, away from moisture and direct heat.
SAFETY NOTE:
Please consult your healthcare professional or physician before use. This medication is not intended for the relief of sudden, acute chest pain attacks. Always ensure your doctor is aware of all other medicines, supplements, or herbal products you are taking to avoid potential interactions.

